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ABSTRACT 
 
OBJECTIVE― WHO, IDF and ADA recommend HbA1c ≥6.5% (48 mmol/mol) for diagnosis 
of diabetes with pre-diabetes 6.0% (42 mmol/mol) [WHO] or 5.7% (39 mmol/mol) [ADA] to 
6.4% (47 mmol/mol). We have compared HbA1c from several methods for research relating 
glycaemic markers. 
 
RESEARCH DESIGN AND METHODS―HbA1c was measured in EDTA blood from 128 
patients with diabetes on IE HPLC analysers (Bio-Rad Variant II NU, Menarini HA8160 and 
Tosoh G8), point of care systems, POCT, (A1cNow+™ disposable cartridges and DCA 
2000®+ analyser), affinity chromatography (Primus Ultra2) and the IFCC secondary reference 
method (Menarini HA8160 calibrated using IFCC SRM protocol). 
 
RESULTS― Median (IQ range) on IFCC SRM was 7.5%(6.8 to 8.4) (58(51 to 68) 
mmol/mol) HbA1c with minimum 5.3%(34 mmol/mol)/maximum 11.9%(107 mmol/mol). 
There were - positive offsets between IFCC SRM and Bio-Rad Variant II NU, mean 
difference (1SD), +0.33%(0.17) (+3.6(1.9) mmol/mol), r2=0.984, p<0.001 and Tosoh G8, 
+0.22%(0.20) (2.4(2.2) mmol/mol), r2=0.976, p<0.001 with  a very small negative difference 
-0.04%(0.11) (-0.4(1.2) mmol/mol), r2=0.992, p<0.001 for Menarini HA8160. POCT methods 
were less precise with negative offsets for DCA 2000®+ analyser  
-0.13%(0.28) (-1.4(3.1) mmol/mol), r2=0.955, p<0.001 and A1cNow+™ cartridges  
-0.70%(0.67) (-7.7(7.3) mmol/mol), r2=0.699, p<0.001 (n=113). Positive biases for Tosoh and 
Bio-Rad (compared with IFCC SRM) have been eliminated by subsequent revision of 
calibration. 
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CONCLUSIONS― Small differences observed between IFCC-calibrated and NGSP certified 
methods across a wide HbA1c range were confirmed by quality control and external quality 
assurance. As these offsets affect estimates of diabetes prevalence, the analyser (and 
calibrator) employed should be considered when evaluating diagnostic data. 
250 words
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HbA1c is important for the management of diabetes [1,2] with its relationship to complications 
described by the Diabetes Control and Complications Trial (DCCT) and United Kingdom 
Prospective Diabetes Study (UKPDS). In both clinical trials ion exchange high performance 
liquid chromatography (IE HPLC) was employed for reporting HbA1c using Bio-Rad analysers 
[3]. More recently, HbA1c has been recommended by the ADA [4], WHO [5] and IDF [6] for 
the diagnosis of diabetes with a level of ≥6.5% (48 mmol/mol) selected as the cut-point 
because of its relationship to diabetic retinopathy in epidemiological studies [7,8].  
 
HbA1c is an attractive alternative to glucose being more stable after collection of blood, not as 
readily affected by short-term variations in glycaemia and not requiring fasting or time 
consuming procedures e.g. oral glucose tolerance testing (OGTT) [9]. It is easily measured in 
laboratories and at point of care (POCT) using a variety of techniques including IE HPLC, 
immunochemistry or boronate affinity chromatography [10]. Precise International Federation 
for Clinical Chemistry and Laboratory Medicine (IFCC) calibrated methods are recommended 
in current guidelines [4-6] following the introduction of the IFCC reference method for HbA1c 
[11] involving mass spectrometry and capillary electrophoresis which has been used to anchor 
calibration of routine methods since 2003.  
 
Rather than a single HbA1c cut-point for diagnosis some guidance from Germany [12] and the 
US [13] recommends using ranges e.g. ≥7.5% (58 mmol/mol) for ruling in diabetes and ≤5.5% 
(37 mmol/mol) for ruling diabetes out with subsequent glucose testing for individuals who fall 
between 5.5% (37 mmol/mol) and 7.5% (58 mmol/mol) [14,15]. Knowledge of any off-sets 
between field methods and IFCC HbA1c values is important when cut-points are being used 
for the diagnosis of diabetes and narrow ranges for pre-diabetes.   
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In this study, we have measured IFCC-calibrated HbA1c in 128 patients with diabetes and 
normal haemoglobin using six systems certified by the National Glycohemoglobin 
Standardization Program (NGSP) and widely used in laboratories and at POCT, Table 1. We 
have compared HbA1c results with an IFCC secondary reference method (IFCC SRM) based in 
a laboratory in the Netherlands comprising an IE HPLC analyser calibrated using special 
IFCC-calibrators. This IFCC SRM is used for the assignment of quality assurance and other 
materials. We have translated the differences observed in HbA1c into effects on estimates of 
the prevalence of diabetes using two data sets from patients undergoing OGTT with 
concurrent HbA1c measurement already published by the authors [15]. In addition, we have 
compared the calibrator used for Tosoh equipment during this study with the revised calibrator 
issued in Europe in September/October 2013 in 45 patient samples stratified across the range. 
 
RESEARCH DESIGN AND METHODS 
Ethical approval for the study was obtained from the West Midlands Local Research Ethics 
Committee and complies with the current revision of the Declaration of Helsinki. 
 
Study Population 
Adult patients attending the diabetes centre for routine care of Type 1 or Type 2 diabetes 
(n=128) with normal haemoglobin were recruited for a research study, Glucose, Fructosamine 
& HbA1c Study (GFH).  HbA1c was measured in EDTA blood samples in the clinical 
biochemistry laboratory and in capillary heparinised blood samples in the diabetes centre 
between June 2007 and June 2009 using laboratory and POCT analysers, Table 1. After 
recruitment ended, HbA1c was also measured in EDTA blood samples in March and April 
2010 on two additional ion exchange HPLC analysers and an IFCC SRM in blood samples 
stored at -70oC, Table 2. 
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HbA1c Methods 
Three IE HPLC analysers, one affinity chromatography analyser and two systems used for 
POCT were compared with an IFCC secondary reference method as described below, Table 1. 
 
Ion Exchange HPLC 
One Tosoh G8 IE HPLC analyser was located in the diabetes centre and another in the 
clinical biochemistry laboratory at University Hospitals Birmingham NHS Foundation 
Trust. The Bio-Rad Variant II NU and Menarini HA8160 IE HPLC analysers were located 
in other laboratories described in the acknowledgements.  The IFCC SRM Menarini 
HA8160 ion exchange HPLC analyser was located in an IFCC secondary reference 
laboratory in the Netherlands. 
 
Point of Care Testing: Immunochemistry 
The A1cNow+TM disposable, hand-held cartridges were calibrated and programmed to perform 
ten analyses with the reagents provided. They contained onboard internal quality control 
(IQC) but additional IQC (Bio-Rad Lyphochek® Diabetes Control Levels 1 and 2) were 
analysed with each batch of samples. Due to limited access to consumables, HbA1c could not 
be measured in all samples, (n=113). Since the study was performed the company have 
specified in their kit leaflet that there is interference from EDTA as evidenced in the latest 
College of American Pathologists (CAP) data [16]. The DCA 2000®+ analyser was calibrated 
using cards specific for each reagent lot. 
 
Boronate Affinity Chromatography 
IQC samples provided by the manufacturer were analysed on the Primus Ultra2 analyser at the 
beginning and end of each batch with two-point calibration.  
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Calibration 
Assays were calibrated in the individual laboratories according to their routine standard 
operating procedures. All manufacturers confirmed the provision of IFCC-calibrators. The 
IFCC SRM Menarini HA8160 IE HPLC analyser was calibrated using the IFCC-network 
three-level calibrator panel (Lot 2009.1021; 2009.1022; 2009.1023). 
 
Recalibration of Tosoh G8 IE HPLC analyser by manufacturer post GFH Study 
In September 2013, Tosoh alerted laboratory staff in Europe to a revision of their calibrator 
with immediate effect via a Product Information leaflet (Release of the new “Hemoglobin 
HbA1c Calibrator Set” Lot ZS3001). The leaflet stated that ‘ For samples with HbA1c values of 
6 to 7% (NGSP) or 42 to 53 mmol/mol (IFCC), variations of 0.1 to  0.2% (NGSP) or 1.4 to  
2.2 mmol/mol (IFCC) can be seen with the new Lot (as compared to the current Lot), 
depending on the specific Lot being used. These variations were deemed acceptable based on 
0.3% (NGSP) criteria.  For samples with HbA1c values <6% and for samples with HbA1c 
values between 7 to 10% (NGSP), a decrease in HbA1c values of ≤0.2% and ≤ 0.3% (NGSP), 
respectively, can be seen with the new Lot (as compared to the current Lot).’ 
As a result of this notification, 45 EDTA blood samples and IQC samples were measured on 
the laboratory Tosoh G8 IE HPLC analyser with the calibrator in use at the time i.e. Lot 
ZS2002 and also after the introduction of the revised calibrator Lot ZS3001.  
 
QC 
IQCs recommended by manufacturers were used with additional materials provided for 
samples processed in batch-mode. 
 
Sample Collection and Storage 
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HbA1c results were available from the diabetes centre on heparinised capillary blood using a 
Tosoh G8 IE HPLC analyser for 112 patients. For the remaining 16 patients, HbA1c was 
measured in venous EDTA blood on a similar analyser in the laboratory, Table 2. 
In addition, HbA1c was measured in the laboratory in EDTA blood using a Primus Ultra2 
affinity chromatography analyser (n=128) and by 2 POCT methods, A1CNow+TM cartridges 
(n=113) and DCA 2000®+ analyser (n=128). Measurements were performed within 5 days of 
collection of blood where possible but if not, samples were stored at -70oC. Note that 
collection into EDTA is not usually performed when blood samples are tested on these POCT 
devices but testing in situ was not possible due to the requirements for obtaining consent for 
the research study from patients. 
 
According to study protocol, 75µl aliquots of 128 EDTA venous whole blood samples were 
prepared in triplicate in 2ml microtubes and stored at -70oC. They were sent by courier on dry 
ice to the outside laboratories for measurement on IFCC SRM, Bio-Rad Variant II NU and 
Menarini HA8160 analysers in March 2010.  The samples were stored at -70oC on receipt and 
not thawed until required.  Samples were analyzed in 6 batches on different days following the 
laboratory’s standard operating procedures along with IQC material (lyophilized Lyphochek® 
levels I and II from Bio-Rad Laboratories Ltd)  provided by the study. This IQC material was 
reconstituted following manufacturer’s instructions, divided into aliquots and stored at -20oC. 
 
Additional Studies 
Duplicate HbA1c measurements were performed on a subsequent assay/day on a sub-set of 
aliquots stratified across the range (n=23) on the IFCC SRM, Menarini HA8160 and 
laboratory Tosoh G8 analysers.  
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Statistical Analysis 
Data were entered into Excel and checked after entry by another person. Statistical analysis 
was performed using Excel and Analyse-it Ver 2.22 (Analyse-it Software Ltd, Leeds, UK).  
HbA1c was reported by the study centre in DCCT aligned units and converted to IFCC using 
the following equation IFCC = (NGSP – 2.15) x 10.929 before analysis. The other laboratories 
reported HbA1c in both IFCC and DCCT aligned units. CVs quoted in the paper were 
calculated from DCCT aligned units (%) but it should be noted that they are higher when 
calculated using IFCC units (mmol/mol) due to the nature of the conversion equation [17].  
 
The different methods for HbA1c measurement were compared to the IFCC SRM with Bland-
Altman difference plots presented for each method [18-20]. Each data point, zero (nil 
difference) lines, mean differences, and 1.96 SD lines are shown. Pearson correlation 
coefficients (r2) were calculated for each assay versus the IFCC SRM. Student’s t-test was 
used to provide p values for the various other comparisons. During the study, the diabetes 
centre Tosoh G7 analyser was updated to a G8 analyser and results re-aligned using a linear 
regression equation derived from samples analysed on both systems (G8 HbA1c = 0.9532*G7 
HbA1c+ 0.1138 (13), n=49). A further re-alignment was required following the release of the 
consensus statement on the worldwide standardisation of HbA1c measurement [21], when 
Tosoh implemented a new ‘anchor’ for their calibrator value. The regression equation 
provided by the manufacturer was as follows; re-aligned HbA1c = 0.917*original HbA1c + 
0.407, n=729. The laboratory Tosoh G8 analyser did not require any re-alignment as all 
analyses on this system took place after this changeover. A national quality assurance scheme 
(NEQAS, UK) classifies the Bio-Rad Variant II NU with other Variant II analysers but Bio-
Rad confirmed that there are no appreciable differences between the various Variant II 
systems. 
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Data sets for patients undergoing OGTT for diagnostic purposes with concurrent HbA1c [15] 
were examined to assess the effect of any offset between routine HbA1c assays and the IFCC 
SRM using probability density function graphs produced for these data sets and also for those 
obtained in this paper for patients referred to a university hospital for treatment of diabetes, 
Figures 2 & 3.  
 
RESULTS 
HbA1c ranged from 5.3% to 11.9% (34 to 107 mmol/mol) for 128 blood samples on the IFCC 
SRM, Table 2. The inter-assay CVs achieved compared well with those quoted by 
manufacturers with the increased scatter for immunoassay POCT methods reflecting 
imprecision, Table 1 & Figure 1. In a stratified subset of 23 samples, there were minimal 
differences between duplicates on IE HPLC analysers with mean difference (1SD) in HbA1c 
on IFCC SRM -0.06%(0.09), p=0.004 (-0.7(0.9) mmol/mol), Menarini HA8160 analyser 
(n=19 only) 0.05%(0.10), p=0.046 (0.5(1.1) mmol/mol) and laboratory Tosoh G8 analyser -
0.02%(0.07), p=0.171 (-0.2(0.8) mmol/mol). 
 
Significant differences in HbA1c were apparent between laboratory/POCT methods and the 
IFCC SRM, all at p<0.001, Table 2, Figure 1. Small positive offsets were observed for the 
Bio-Rad Variant II NU analyser +0.33% HbA1c (3.6 mmol/mol) and Tosoh G8 analyser 
located in the diabetes centre +0.22% HbA1c (2.4 mmol/mol). For the Menarini HA8160 
analyser situated in a routine hospital laboratory, there was a very small offset -0.04% HbA1c 
(-0.4 mmol/mol) similar to the differences observed between duplicates. There were negative 
biases for Primus Ultra2 affinity chromatography analyser, -0.23% HbA1c (-2.5 mmol/mol) 
and   DCA 2000®+ immunoassay analyser, -0.13% HbA1c (-1.4 mmol/mol). These differences 
in bias between methods were confirmed by internal quality control results obtained for the 
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study and in national external quality assessment schemes. The difference in A1cNow+TM 
disposable, immunoassay cartridges of -0.7% HbA1c (-7.7 mmol/mol) in EDTA blood is 
similar to that observed in College of American Pathologists (CAP) data for 2013 [16] and 
may be attributed to the presence of EDTA. When 23 EDTA blood samples were re-measured 
at the end of the study on the laboratory Tosoh G8 IE HPLC analyser after being frozen at -
70oC, the  higher bias for Tosoh G8 IE HPLC analyser versus IFCC SRM was confirmed, 
+0.30%(0.12) (+3.3(1.3) mmol/mol) HbA1c, p<0.001. 
 
 In Birmingham, UK, 1457 patients with impaired fasting glucose (6.1 to 6.9 mmol/L) were 
referred by their family doctors for OGTT for diagnosis of diabetes with HbA1c measured on a 
Tosoh G8 analyser at the diabetes centre [15]. In Melbourne, Australia, 4083 patients at risk of 
diabetes for various reasons were referred for OGTT with HbA1c measured on a Bio-Rad 
Variant II Turbo analyser. Patients with abnormal haemoglobins were excluded from both 
datasets [15]. Figure 2 shows the effect of the small offsets identified in this study on the 
prevalence of diabetes when HbA1c was measured on different IE HPLC analysers in these 
two populations. Probability density plots for both the method comparison reported in this 
paper and OGTT data sets, Figure 3, highlight the differences in the distributions of HbA1c for 
patients with diabetes and those being diagnosed with diabetes and also the bias of the 
different methods used for HbA1c measurement.  
 
Introduction of the revised Tosoh calibrator in October 2013 resulted in a decrease in HbA1c 
values as outlined in the product information sheet i.e. an offset across the range of HbA1c as 
identified in the GFH Study versus the IFCC SRM. On calibrator lot (ZS2002) comparable to 
that used for this paper, HbA1c was 7.5 (6.3 to 9.7)%, (58 (46 to 83) mmol/mol), median IQ 
range, in 45 blood samples with minimum 5.4% (36 mmol/mol) and maximum 12.3% (111 
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mmol/mol) compared to 7.4 (6.2 to 9.6)%, (57 (44 to 81) mmol/mol, 5.4%  (35) mmol/mol 
and 12.0% (108 mmol/mol), respectively, for the revised calibrator (ZS3001), r2 =0.999, 
p<0.0001. The difference (mean 1SD) between the calibrators (revised [RC] minus GFH 
study equivalent [PC]) was  -0.23(0.06)% or -2.5(0.6) mmol/mol, Figure 1c,  with linear 
regression equation , HbA1c[RC]  = -0.044 + 0.9866 HbA1c[PC]  in %  or  HbA1c[RC]  = -0.797 
+ 0.9866 HbA1c[PC]  in mmol/mol. The change in assay bias on revision of the calibrator was 
also reflected in IQC as indicated by the additional leaflet Calibrator and Control Values 
when using Calibrator lot ZS3001 that introduced new ranges for IQC issued in September 
2013 by Tosoh.   
 
CONCLUSIONS  
Changes in HbA1c of 0.5% (6 mmol/mol) to 1.0% (11 mmol/mol) or greater within a patient 
are considered clinically significant for the management of diabetes [22] with targets of 6.5% 
(48 mmol/mol) or 7.5% (58 mmol/mol) depending on circumstances. However, now that a 
single HbA1c cut-point ≥6.5% (48 mmol/mol) is recommended for diagnosis of diabetes with 
pre-diabetes defined as 5.7% (39) or 6.0% (42 mmol/mol) to 6.4% (47 mmol/mol) HbA1c [5], 
the criteria for assessing the performance of HbA1c assays have changed as small variations in 
assay performance will result in the movement of people from one category to another.  
 
Although routine methods for measuring HbA1c are calibrated using the IFCC reference 
method, it is important to know whether there are any differences in the accuracy and 
imprecision of IFCC-calibrated and NGSP certified methods that will affect diagnostic 
procedures. In this study, the values obtained for HbA1c from two IE HPLC laboratory 
analysers were significantly higher than the IFCC SRM across the range of blood samples as a 
constant unrelated to glycation.  A small positive HbA1c offset of 0.22% (2.4 mmol/mol) IFCC 
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(mean difference) was identified for the Tosoh G8 IE HPLC analyser, p<0.001, and 0.33% 
(3.6 mmol/mol) for Bio-Rad Variant II NU IE HPLC analyser, p<0.001, compared with the 
IFCC SRM. The difference between the Menarini HA8160 IE HPLC analyser located in a 
routine hospital laboratory was significant, p<0.001, but much smaller at -0.04% (-0.4 
mmol/mol) although this is not surprising as it is the same IE HPLC analyser as that used for 
the IFCC SRM but calibrated using the manufacturer’s rather than IFCC SRM calibrators.  
 
The offsets observed for particular HbA1c assays studied would result in different proportions 
of people being diagnosed with diabetes depending on the assay used. Translation of the 
positive biases observed in this study performed between 2007 and 2010 down to IFCC SRM 
HbA1c values in two populations presenting for OGTT would result in a lowering of the 
prevalence of diabetes by approximately one third i.e. from 36% to 22% for HbA1c results 
obtained using a Tosoh G8 analyser in Birmingham, UK and from 24% to 15% for the Bio-
Rad analyser used in Melbourne, Australia, Figure 2. Since this study was performed, we have 
been informed that Bio-Rad adjusted their calibration to account for this positive bias as 
evidenced by the CAP review for 2013 [16].  
 
For another laboratory analyser involving affinity chromatography, there was a negative 
difference of -0.23% (-2.5 mmol/mol) HbA1c compared with IFCC SRM, p<0.001, giving 
possible differences in HbA1c between routine laboratory analysers of up to 0.6% (6 
mmol/mol). Use of this analyser would lead to an underestimation of the prevalence of 
diabetes compared with the IFCC SRM.  Bias can be introduced during the calibration process 
despite acceptable imprecision due to matrix effects in artificial calibration materials rather 
than blood, Figure 3. These small differences observed between laboratory/POCT methods are 
within the limits of accuracy for NGSP certification.  
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This study is limited because only a few analysers were involved with particular batches of 
assay consumables and calibrators. In addition, some samples were measured at the end of the 
study after storage at -70oC. However, the results are in line with manufacturers’ expectations 
and confirmed in internal quality control and national external quality assurance schemes e.g. 
United Kingdom National External Quality Assessment Service (UK NEQAS) and CAP. The 
performance of the A1cNow+TM disposable cartridges may have been be affected by EDTA as 
the company have since reported interference from EDTA in kit inserts published after the 
study was completed. This paper does not include widely used immunoassays available on 
routine automated clinical chemistry analysers that do not detect abnormal haemoglobins. In a 
recent publication comparing an immunoassay method with a Bio-Rad IE HPLC analyser, the 
correlation quoted was r2 =0.996 but readings of 9.5% (80 mmol/mol) for Bio-Rad and 8.6% 
(70 mmol/mol) on the Cobas c502 [23] were apparent on the scattergram.  
 
These differences between IFCC-calibrated methods are in line with some attributed to 
populations in research studies without due consideration of the analyser employed for HbA1c 
measurement [24-28]. In our previously published paper relating OGTT data to concurrent 
HbA1c in the UK and Australia, it was unclear whether the differences in HbA1c ranges quoted 
were related to the population, sampling or analysers [15,25]. In Birmingham, HbA1c was 
measured using the Tosoh G8 situated in the diabetes centre (as described in this paper) and in 
Australia using a Bio-Rad Variant II analyser – analysers with similarly high biases versus the 
IFCC SRM as observed in this study. Inspection of the HbA1c distribution in these two 
populations in Figure 2 shows how the differences between results from routine IFCC-
calibrated methods would impact on the number of patients being diagnosed with diabetes 
[29].  Figure 3 demonstrates the requirements for the performance of HbA1c assays now based 
on the differing populations presenting for diagnosis or treatment. It is worth noting that since 
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the introduction of HbA1c for diagnosis of diabetes in Birmingham in June 2012, the HbA1c 
workload in our hospital laboratory has increased by 75% during the year since then with only 
a few OGTTs being performed. 
 
In September/October 2013, Tosoh introduced a new calibrator that revised their HbA1c values 
downwards, yielding results similar to the Menarini analysers in this study and the Bio-Rad IE 
HPLC analyser after introduction of a revised calibrator. The Tosoh IE HPLC data presented 
in this paper has not been realigned to the new revised calibrator but the comparison data from 
October 2013 shows that the bias detected in this study compared with the IFCC secondary 
reference method has been eliminated, Figure 1c.  
 
In conclusion: currently there is some debate about the particular requirements for the 
performance of IFCC-calibrated and NGSP certified HbA1c assays for diagnostic purposes in 
addition to the treatment of patients with diabetes. Although using HbA1c for diagnosis has 
been subject to systematic review [30] following much debate about its relationship to OGTT 
[31,32], the methods used for HbA1c measurement are rarely discussed. Small differences i.e. 
offsets between IFCC-calibrated methods identified in this study across a wide range of HbA1c 
values would affect estimates of the prevalence of diabetes markedly. When evaluating HbA1c 
in individuals/populations, it is important to consider the method used for HbA1c measurement 
(and any revisions to calibration by the manufacturers) especially when HbA1c is being used 
for diagnostic purposes [33]. 
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Table 1—Information on HbA1c Methods from Manufacturers and GFH study 
*obtained from DCCT values 
Analyser Principle 
Detects variant 
hemoglobin Conversion equation Assay range 
Manufacturer 
inter-assay 
CV* 
low/high 
Study 
inter-assay 
CV* 
Bayer A1cNow+™ Immuno-chemistry No NGSP = 0.0915*IFCC + 2.15 
4% to13% 
20 to 119 mmol/mol 3.0% to 4.0% 4.8%/6.3% 
Bio-Rad 
VARIANT II NU IE HPLC Yes NGSP = 0.09148*IFCC + 2.152 
3.1% to 18.5% 
10 to 179 mmol/mol <2.0% 1.5%/1.2% 
IFCC SRM IE HPLC Yes NGSP = 0.0915*IFCC + 2.15 all physiological values 1.3%/1.4% 1.0%/0.6% 
Menarini HA8160 IE HPLC Yes IFCC = (NGSP  –  2.15)*10.929 all physiological values 1.3%/1.6% 1.0% /1.3% 
Primus Ultra2 
Affinity 
chromato- 
graphy 
No IFCC = (NGSP – 2.15)/0.0915 2% to 25% -2 to 250 mmol/mol <2.0% 1.7%/1.5% 
Siemens DCA 2000®+ Immuno-chemistry 
No but HbA1c 
reported for Hbs 
S & C 
IFCC = (10.93*NGSP – 23.50) 2.5% to 14.0% 4 to 130 mmol/mol 2.2% to 3.2% 1.6%/4.6% 
Tosoh G8 IE HPLC Yes NGSP =  (0.09148*IFCC) + 2.152 2.4% to 22.3% 3 to 220 mmol/mol <2.0% 
1.2%/1.0% 
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Table 2—Comparison of HbA1c from IFCC-calibrated Field Methods with an IFCC Reference Method, n=128  
Method  
Median 
(IQ range) 
% 
mmol/mol 
Minimum 
to 
maximum 
% 
mmol/mol 
Mean 
difference 
(SD) % 
mmol/mol r2 p value 
Bayer A1cNow+™* 6.7 (6.1 to 7.4) 4.9 to 11.1 -0.70 (0.67) 0.70 <0.001 
 50 (43 to 57) 30 to 98 -7.7 (7.3)   
Bio-Rad VARIANT II NU** 7.8 (7.1 to 8.8) 5.7 to 12.3 0.33 (0.17) 0.98 <0.001 
 62 (54 to 73) 39 to 111 3.6 (1.9)   
IFCC SRM** 7.5 (6.8 to 8.4) 5.3 to 11.9 - - - 
 58 (51 to 68) 34 to 107    
Menarini HA8160**  7.5 (6.7 to 8.4) 5.3 to 12.2 -0.04 (0.11) 0.99 <0.001 
 58 (50 to 68) 34 to 110 -0.4 (1.2)   
Primus Ultra2*** 7.3 (6.6 to 8.1) 5.4 to 11.3 -0.23 (0.28) 0.95 <0.001 
 56 (49 to 65) 36 to 100 -2.5 (3.1)   
Siemens DCA 2000®+*** 7.3 (6.7 to 8.1) 5.2 to 13.2 -0.13 (0.28) 
 
0.95 
 
<0.001 
 56 (50 to 65) 33 to 121 -1.4 (3.1)   
Tosoh G8† 7.8 (7.0 to 8.6) 5.3 to 12.2 0.22 (0.20) 0.98 <0.001 
 62 (53 to 70) 34 to 110 2.4 (2.2)   
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*n=113 **Stored at -70OC ***Samples measured fresh or after storage at -70OC †112 samples capillary heparinised blood 
measured in diabetes centre and 16 samples venous EDTA blood measured in laboratory  
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FIGURE LEGENDS  
 
Figure 1a  
Scatterplot with linear regression lines for HbA1c measured by different IFCC-calibrated field methods and IFCC SRM, n=128. 
 
 
 
Figure 1b 
Difference plots for HbA1c measured by IFCC-calibrated field methods versus IFCC SRM, n=128. 
Colours of symbols as per Figure 1a, ― zero line, --- mean difference & …. 1.96 SD 
 
Figure 1c 
Difference plot as above for Tosoh G8 IE HPLC analyser post recalibration (ZS3001) by manufacturer in 
September/October 2013 versus calibrator (ZS2002) with a bias equivalent to those calibrators used in the GFH Study, 
n=45. 
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Figure 2 
 
Effects of bias of IE HPLC assays on prevalence of diabetes in patients presenting for OGTT with concurrent HbA1c in 
Birmingham and Australia 
 
   4083 Australian patients with risk factors for diabetes (Bio-Rad Variant II Turbo IE HPLC analyser) 
  1457 UK patients with impaired fasting glucose, 6.1 – 6.9 mmol/L (Tosoh G8 IE HPLC analyser) 
Figure 3 
 
Probability density functions for HbA1c in patients presenting for OGTT and from the comparison of analytical methods in 
patients with diabetes 
 
Colours of symbols as per Figure 1a 
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Figure 1a  
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Figure 1b 
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Figure 1c 
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Figure 2 
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Figure 3 
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